Physician profile
Shobit Rastogi
NPI 1720062763
$34,143.54
in general payments reported to CMS, 2019-2025
26 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,962 · 2021: $9,715 · 2022: $1,383 · 2023: $969 · 2024: $2,249 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700 · Travel and Lodging: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.22 |
| Travel and Lodging | $1,325.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $23,493.97 | 2019-2021 | |
| Ivantis, INC | $2,834.06 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $2,099.30 | 2022-2025 | Envista Aspire Iol, Teneo, Stellaris Elite |
| New World Medical,INC. | $1,803.43 | 2019-2022 | |
| Alcon Vision LLC | $1,262.35 | 2019-2025 | Clareon, Rocklatan, Lensx |
| Abbvie INC. | $585.84 | 2022-2025 | |
| Allergan, INC. | $574.08 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $283.74 | 2020-2025 | |
| Sight Sciences, INC. | $263.55 | 2019-2024 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $171.60 | 2019 | |
| Amgen INC. | $115.06 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $111.15 | 2019-2021 | |
| Biotissue Holdings INC. | $90.03 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $62.99 | 2019 | |
| Optinose US, INC. | $60.80 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $55.43 | 2025 | |
| Eyevance Pharmaceuticals LLC | $50.70 | 2020-2022 | |
| Oyster Point Pharma, INC. | $43.43 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.95 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $28.33 | 2024 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $24.28 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $23.38 | 2023 | Ryaltris |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $18.29 | 2023 | Tepezza |
| Stryker Corporation | $16.04 | 2025 | Audion Et Dilation System |
| Akorn Operating Company LLC | $14.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shobit Rastogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.